SavedAdd your journal

Journals / Güncel Retina Dergisi / 2019 / Cilt: 3 - Sayı: 1

Intravitreal Bevacizumab Injection and Treatment Regimens in Macular Edema Due to Central Retinal Vein Occlusion

Santral Retinal Ven Tıkanıklığına Bağlı Makula Ödeminde İntravitreal Bevacizumab Enjeksiyonu ve Tedavi Protokolleri

Gökhan DEMİR
Dilek YASA
Pages
35–39
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In current review, the treatment options will be evaluated briefly and the efficacy and safety of bevacizumab will be discussed in greater detail.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Central retinal vein occlusion (CRVO) is the second most common vascular disease leading cause of vision loss together branch retinal vein occlusion (BRVO) after diabetic retinopathy (DR).
📊
Key Findings & Data:Several studies have demonstrated that bevacizumab is effective in improving vision and decreasing central macular thickness when used in patients with macular edema due to central retinal vein occlusions.
💡
Conclusion & Impact:In current review, the treatment options will be evaluated briefly and the efficacy and safety of bevacizumab will be discussed in greater detail.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Central retinal vein occlusion (CRVO) is the second most common vascular disease leading cause of vision loss together branch retinal vein occlusion (BRVO) after diabetic retinopathy (DR). Vision loss due to CRVO is commonly caused by macular edema and multiple treatment modalities have been used to treat macular edema. In clinical practice, VEGF inhibitors are now the first-line treatment offered to patients who have CRVO with macular edema. The two agents approved by the FDA for treatment of macular edema are aflibercept and ranibizumab. Bevacizumab is another VEGF inhibitor that has been used off-label to treat macular edema. Several studies have demonstrated that bevacizumab is effective in improving vision and decreasing central macular thickness when used in patients with macular edema due to central retinal vein occlusions. In current review, the treatment options will be evaluated briefly and the efficacy and safety of bevacizumab will be discussed in greater detail.

Özet

Santral retinal ven tıkanıklığı (SRVT), diyabetik retinopatiden sonra retina ven dal tıkanıklığı (RVDT) ile birlikte görme kaybına sebep olan ikinci en sık görülen vasküler hastalıktır. SRVT’da görme kaybı çoğu zaman makula ödeminden (MÖ) kaynaklanmakta ve MÖ’yü tedavi etmek için birçok tedavi modalitesi kullanılmaktadır. Klinik pratikte, şimdi vasküler büyüme faktörü inhibitörleri (anti-VEGF) MÖ olan hastalarda tercih edilen birinci basamak tedavidir. MÖ tedavisinde FDA onaylı iki ajan ranibizumab ve aflibercepttir. Bevacizumab ise MÖ tedavisinde ruhsatsız kullanılan başka bir anti-VEGF’tir. Birçok çalışma, bevacizumabın SRVT’ye bağlı MÖ’de kullanıldığında görme keskinliğini iyileştirme, merkezi makula kalınlığını (MMK) azaltmada etkili olduğunu göstermiştir. Bu derlemede tedavi seçenekleri kısaca ele alınacak ve bevacizumab etkinliğini ve güvenliğini daha ayrıntılı olarak tartışılacaktır.

🔖

Cite This Article

DEMİR, G., YASA, D. (2019). Intravitreal Bevacizumab Injection and Treatment Regimens in Macular Edema Due to Central Retinal Vein Occlusion. Güncel Retina Dergisi, Cilt: 3 - Sayı: 1, 35–39. https://ajindex.com/articles/162612

References (13)

  1. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: An evidence‑based systematic review. Ophthalmology 2010;117(6):1094‑101.e5
  2. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-9.e1
  3. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: Review of the literature. Eye (Lond) 2011;25(8):981-8
  4. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996;114(10):1243-7
  5. Kolar P. Risk factors for central and branch retinal vein occlusion: A meta- analysis of published clinical data. J Ophthalmol 2014;2014:724780
  6. Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal veinocclusion. Cochrane Database Syst Rev 2013;(1):CD009510
  7. Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2014;(5):CD007325
  8. Clarkson JG, Chuang E, Gass D, Pedroso M, Cubillas T, Duria ES et al. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology. 1995;102(10):1434–1444
  9. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 2011;118(1):119-33. e1-2
  10. Hayreh SS, Zimmerman MB. Ocular neovascularization associated with central and hemicentral retinal vein occlusion. Retina. 2012;32(8):1553–1565
  11. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999;106(11):2054–2062
  12. Clarkson JG, Chuang E, Gass D, Pedroso M, Cubillas T, Duria ES et al. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology. 1995;102(10):1425–1433
  13. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al. The SCORE Study Research Group, A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associate